icon-    folder.gif   Conference Reports for NATAP  
 
  XIX International AIDS Conference
July 22-27, 2012
Washington, DC
Back grey_arrow_rt.gif
 
 
 
Phase 1/2, Multicenter, Open-label, Pharmacokinetic, Safety, Tolerability, and Antiviral Activity Study of Dolutegravir (DTG), a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children, and Adolescents: P1093
 
 
  Reported by jules Levin
19th Intl AIDS Conf July 22-27 2012 Wash DC
 
Rohan Hazra, Rolando Viani, Edward Acosta, Nan Zheng, Carmelita Alvero, Ellen O'Gara, Elizabeth Petzold, Barb Heckman, Debra Steimers, Ivy Song, Steve Piscitelli, Andrew Wiznia, on behalf of the P1093 Study Team

IAC1.gif

IAC2.gif

IAC3.gif

IAC4.gif

IAC5.gif

IAC6.gif